Letters to the Editor http://www.nature.com/oby/journal/v19/n1/full/oby2010107a.html
Obesity (2011) 19 1, 2. doi:10.1038/oby.2010.107
Richard L. Atkinson Obetech Obesity Research Center, Richmond, Virginia, ratkinson2 at vcu.edu)
TO THE EDITOR: The article titled “Lack of Evidence for the Role of Human Adenovirus-36 in Obesity in a European Cohort” by Goossens et al. (1) reports a very low prevalence of human adenovirus-36 (Ad-36) and no evidence of association with obesity in 540 Dutch and Belgian individuals. There are several concerns with this article. First, the findings are in contrast to other papers in the literature from the United States, Italy, and Korea (2,3,4,5,6,7,8). We reported that 30% of obese and 11% of nonobese US adults had Ad-36 antibodies and a strong association with obesity (P < 0.001) (2). We found a 30% prevalence of Ad-36 antibodies in obese children in Korea and a strong association with obesity (P < 0.01) (3). Na et al. (4) found Ad-36 antibodies in 29% of obese and 14% of nonobese children in Korea. Trovato et al. (5,6) in two studies from Italy noted a prevalence of Ad-36 antibodies of >40% and an association with obesity. Broderick et al. (7) did not find an association of Ad-36 with obesity in military personnel in San Diego, California, but the prevalence of antibodies was 37%. Gabbert et al. (8) presented a study at the Annual Meeting of The Obesity Society in October 2009, showing a prevalence of 22% in obese children and 7% in lean children in San Diego with a strong association with BMI.
A personal communication attributed to me that 8% of Belgians were Ad-36 positive was described in the Goossens et al.'s article, but this needs to be clarified as it was not intended for publication. The almost 15-year-old study was that of another investigator for whom we measured the Ad-36 antibodies in a relatively small number of patients, and I cannot recall the specific percentage. Unfortunately, the original data are not available to me now.
Of more concern, one of the authors of this article sent 25 samples of serum to my laboratory in 2007 because their assay found a very low prevalence of Ad-36 antibodies in their population. We found that 9 of the 25 (36%) were positive by serum neutralization assay. These findings are in contrast to the results reported in the Goossen et al.'s article from subjects presumably from the same area. Goossens et al. also reported that they were unable to find Ad-36 DNA by PCR assay in 31 adipose tissue samples. We found Ad-36 DNA in 25% of adipose tissue samples from obese and severely obese people in the United States (9).
A potential explanation of the differences between the Goossens et al.'s article and previous publications may be problems with the assays. We have concerns about human serum samples being repeatedly frozen and thawed as we have observed that the antibody titers in such samples seem to decrease. The authors stated that the rabbit serum positive control that I had sent to one of the authors in 2007 did not demonstrate any loss of titer upon repeated freezing. However, this antibody was produced by injecting an Ad-36 vaccine into a rabbit and we postulate that it may not be an appropriate control for human serum. As for the PCR assay for Ad-36, we have found it to be very difficult to perform and sensitive to the method of collection, method of DNA extraction, and type of primers and probe used. Ad-36 DNA is present in low concentration in adipose tissue. The authors used only 10 mg of adipose tissue, which is considerably less than what we and Dhurandhar's group use (10). Adipose tissue has many fewer cells for weight due to the large amounts of stored triglycerides so larger amounts of tissue are needed. Also, the authors did not use the same PCR method that has been reported by us and other authors (9,10,11).
Finally, the conclusions of this article may overreach the data. The authors propose that “Ad-36 does not play a role as a direct cause of BMI increase and obesity in humans in Western Europe.” However, if correct, their data apply only to Belgium and The Netherlands. Italy is in Western Europe and the Italian publications show ~43% of total subjects were positive and that there was a strong correlation of Ad-36 with obesity (5,6).
Conflict of interest
Obtech provided assays for detection of Ad-36 and has several patents regarding Ad-36 assays.
Goossens VJ, Dejager SA, Grauls GE et al. Lack of evidence for the role of human adenovirus-36 in obesity in a European cohort. Obesity (Silver Spring) 2009; e-pub ahead of print.
Atkinson RL, Dhurandhar NV, Allison DB et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond) 2005;29:281–286. | Article | PubMed | ChemPort |
Atkinson RL, Lee I, Shin HJ, He J. Human adenovirus-36 antibody status is associated with obesity in children. Int J Pediatr Obes 2009; e-pub ahead of print 10 July 2009.
Na HN, Hong YM, Kim J et al. Association between human adenovirus-36 and lipid disorders in Korean schoolchildren. Int J Obes (Lond) 2010;34:89–93. | Article | PubMed
Trovato GM, Castro A, Tonzuso A et al. Human obesity relationship with Ad36 adenovirus and insulin resistance. Int J Obes (Lond) 2009;33:1402–1409. | Article | PubMed | ChemPort |
Trovato GM, Martines GF, Garozzo A et al. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int 2009; e-pub ahead of print 13 October 2009.
Broderick MP, Hansen CJ, Irvine M et al. Adenovirus 36 seropositivity is strongly associated with race and gender, but not obesity, among US military personnel. Int J Obes (Lond) 2009; e-pub ahead of print 10 November 2009.
Gabbert CG, Arnold J, Schwimmer J. Adenovirus-36 Infection and Obesity in Children and Adolescents. Oral abstract, Obesity Society Annual, Wash., DC http://www.obesity.org/obesity2009/2009_Abstracts/2009_Oral_Abstracts.pdf (2009).
Salehian B, Forman SJ, Kandeel FR et al. Adenovirus 36 DNA in adipose tissue of patient with unusual visceral obesity. Emerg Infect Dis 2010;16:850–852. | PubMed |
Dhurandhar NV, Whigham LD, Abbott DH et al. Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr 2002;132:3155–3160. PubMed ISI ChemPort
Rogers PM, Mashtalir N, Rathod MA et al. Metabolically favorable remodeling of human adipose tissue by human adenovirus type 36. Diabetes 2008;57:2321–2331. Article PubMed ChemPort
author is president of Obetech and Editor of the International Journal of Obesity
Note: Contacted Obetech Feb 2012: they do not have rate of increase data
PDF for this letter to the editor is attached to this page
Adenovirus review is attached to this page
Canaries in the coal mine - Adenovirus-36 increase in mammal weight file - even for animals living near humans
Items in both categories Obesity nd Virus are listed here:
- Co-Epidemic of Obesity and COVID-19 (a co-epidemic of Vitamin D not mentioned) – April 2021
- COVID-19 hospitalizations: 63% associated with diabetes, obesity, hypertension or heart failure – Feb 2021
- Light case of COVID-19 in immunocompromised obese man with many comordities but good level of vitamin D – March 2021
- Obese get less benefit from vaccines: influenza, hepatitis B, rabies and now COVID-19 - March 2021
- 26 health factors increase the risk of COVID-19 – all are associated with low vitamin D
- Virus (adeno-36) increases Obesity which then increases risk of another virus (Influenza) - Oct 2013
- Increased weight in children 8X more likely for each unit increase in adenovirus (if ignore Vitamin D) – Nov 2019
- 25 year review of Adenovirsus and obesity – 2018
- Adenovirus-36 is strongly associated with Obesity (possibly prevented and treated by Vitamin D)
- Adenovirus-36 association with obesity letter to editor – 2011
- Obesity pandemic since 1975 - is it due to Vitamin D, Magnesium, Iodine, adenovirus, or what
- Low vitamin D then Obesity then adenovirus-36